Bergamo, Italy
Bergamo, Italy

Time filter

Source Type

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the Bank of America Merrill Lynch (BAML) 2017 Health Care Conference in Las Vegas and at the Jefferies (Jefferies) 2017 Global Healthcare Conference in New York City. The discussion at the BAML conference is scheduled to begin at 9:20 a.m. Pacific Time on Tuesday, May 16, and the discussion at the Jefferies conference is scheduled to begin at 3:00 p.m. Eastern Daylight Time on Thursday, June 8. Both discussions will be available to all interested parties through a live audiocast accessible via the investor relations section of LivaNova’s website at http://investor.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. A replay of the webcast will be available on the LivaNova website approximately 24 hours after the live presentation for 90 days after the event. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. For more information, please visit www.livanova.com.


(PRLEAP.COM)– According to a new series of reports on the U.S. market for diagnostic ophthalmic devices by iData Research ( www.idataresearch.com ), manufacturers are introducing new technologies into fundus camera systems, including angiography and fluorescent dye tracking. As a result, total fundus camera unit sales are moderately growing. Table mounted sales for both imaging modalities are being driven by the replacement of older technology. The natural growth of the market associated with the increase in the elderly populations which is directly correlated with the incidence of ocular disease.This market includes mydriatic and non-mydriatic fundus cameras. Each of the segments are further divided into table mounted and handheld devices. The persistent growth of the market is driven by the prevalence of age-related ocular conditions, such as glaucoma and macular degeneration. However, the average selling price for the total fundus camera market will depreciate over the next several years. This decrease can partially be attributed to the influx of inexpensive handheld devices and the competitive nature of the market that is being seen across all fundus camera segments. As a result, the significantly less expensive handheld mydriatic market is strongly outpacing the unit growth of the established table mounted market. Furthermore, the table mounted market is losing ground to combination devices which incorporate fundus cameras into other ophthalmic equipment."Traditionally the non-mydriatic fundus camera has been the choice of optometrists for several reasons; it is less expensive, the additional capabilities were not used as much by optometrists, and the need for chemical pupil dilation was an inconvenience for patients post procedure," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "This is beginning to change as the increased range of capabilities offered by mydriatic cameras can also be a competitive advantage for an optometrist seeking patients."Topcon is the leading competitor in the U.S. fundus camera market. The company manufactures table mounted fundus cameras for both the mydriatic and non-mydriatic market. As part of the table mounted non-mydriatic fundus cameras Topcon manufactures the TRC-NW8®, TRC-NW8F® and the TRC-NW400®. In the mydriatic market Topcon manufactures the TRC-50DX® Series.Carl Zeiss Meditec is the second leading competitor in the U.S. fundus camera market. The company manufactures five fundus cameras, and participates in all segments of this market. Their latest fundus camera, the VISUCAM® 224 has a 24-megapixel sensor for high resolution images. Additional competitors in the U.S. fundus camera market include Canon and Kowa among others.More on the fundus camera market in the U.S can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Diagnostic Ophthalmic Devices . The suite covers reports on the following markets: Ophthalmic coherence tomography, fundus cameras, data management systems, slit lamps, perimeters, tonometers, autorefractors/keratometers, binocular indirect ophthalmoscopes, ophthalmic ultrasound devices, wavefront abberometers, corneal topographers and optical biometers.The iData report series on ophthalmic devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about ophthalmic device market data, register online or email us at info@idataresearch.net for a U.S. Market Report Suite for Diagnostic Ophthalmic Devices brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Dental Operatory Equipment and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


LONDON--(BUSINESS WIRE)--LivaNova, PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, announced today that the company will unveil three data presentations on the PercevalTM sutureless valve at the upcoming American Association for Thoracic Surgery (AATS) Centennial meeting, which will be held from April 29 – May 3, 2017 in Boston. The data presentations showcase Perceval’s safety and performance for aortic valve replacement (AVR) patients. This year, the annual AATS meeting celebrates 100 years of the conference and the specialty of cardiothoracic surgery. Along with the commemoration of a century of AATS, LivaNova marks 10 years of clinical use with the Perceval valve for patients in need of AVR and more than 30 years of innovation in cardiac surgery. “Since its introduction a decade ago, Perceval has provided surgeons with an innovative, safe and effective aortic valve replacement solution that can lead to enhanced patient outcomes. As the only truly sutureless surgical aortic valve replacement option, Perceval has been used for simple to complex patient types,” said Bart Meuris, M.D., Ph.D., UZ Leuven, Belgium. The Perceval valve optimizes the overall surgical approach for cardiac surgeons by enhancing the speed and efficiency of procedures while providing excellent hemodynamic performance. It has been implanted in more than 20,000 patients in over 310 hospitals in 34 countries across the world. “With more than three decades of innovation in cardiac surgery, LivaNova is committed to developing innovative solutions, like Perceval, which is the only truly sutureless valve for AVR, and expanding our extensive portfolio of advanced technologies,” said Brian Duncan, M.D., Vice President, Medical Affairs, Cardiac Surgery at LivaNova. “Looking ahead to the next 50 years, we strive to continue leading the advancement of innovative cardiac surgery solutions to improve the lives of patients around the world.” In addition to recognizing 10 years of clinical use with Perceval, LivaNova celebrates key milestones in cardiac surgery innovation: Three presentations related to Perceval will occur during the AATS meeting: Tuesday, May 2 “Prospective U.S. IDE Trial of a New Sutureless Aortic Bioprosthesis in Standard Risk Surgical Patients: One Year Hemodynamic, Clinical and Functional Outcomes” Rakesh M. Suri, Hoda Javadikasgari, David Heimansohn, Neil Weissman, Gorav Ailawadi, Niv Ad, Gabriel Aldea, Vinod Thourani, Wilson Szeto, Robert Michler, Hector Michelena, Reza Dabir, Bartley Griffith, Eric E. Roselli Late Breaking Trial, 12:45 p.m. Wednesday, May 3 “Sutureless Aortic Valves Versus Transcatheter Aortic Valve in Patients with Severe Aortic Stenosis and Intermediate Risk Profile: A Propensity Match Comparison in the Real World” Claudio Muneretto, Alberto Repossini, Lorenzo Di Bacco, Roberto Di Bartolomeo, Carlo Savini, Gianluca Folesani, Manfredo Rambaldini, Maurizio Tespili, Juan Pablo Maureira, Francois Laborde, Thierry Folliguet Adult Cardiac Surgery Simultaneous Session, 7:30 a.m. To learn more about Perceval and its patient benefits, please visit LivaNova at booth exhibit 1622 or visit www.heartvalvesurgery.com/sutureless. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. For more information, please visit www.livanova.com.


LONDON--(BUSINESS WIRE)--LivaNova, PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, announced the presentation of data from multiple studies demonstrating the safety and the effectiveness of the PercevalTM sutureless valve for Aortic Valve Replacement (AVR) patients and the Memo 3D ReChordTM for mitral valve repair. The three data presentations on Perceval, which included a late-breaking clinical trial and a poster presentation on the Memo 3D ReChord, were unveiled at the American Association for Thoracic Surgery (AATS) Centennial meeting in Boston on April 29 – May 3, 2017. “For more than 30 years, LivaNova has been dedicated to creating and delivering safe, superior and innovative technology, like the Perceval sutureless valve and Memo 3D ReChord. We are proud to unveil these new clinical results which underscore our legacy and commitment to develop best-in-class cardiac solutions in the aortic and mitral field,” said Brian Duncan, M.D., Vice President, Medical Affairs, Cardiac Surgery at LivaNova. “Also, as we celebrate the 10th anniversary of Perceval's introduction into the AVR treatment process, we are encouraged to continue supporting cardiac surgeons to advance the standard of care and enhance the lives of patients worldwide.” Key data presented included the late-breaking clinical trial presentation, “Prospective US IDE Trial of a New Sutureless Aortic Bioprosthesis in Standard Risk Surgical Patients: One Year Hemodynamic, Clinical and Functional Outcomes,” which found that Perceval was a safe and effective AVR valve in surgical patients. The prospective, single-arm clinical trial consisting of 300 patients demonstrated that following sutureless valve therapy support, patients experienced hemodynamic relief from aortic stenosis and improvement in quality of life. At one-year follow up, health-related quality of life score increased from 63.2±22 before surgery to 85.4±18.1 at follow up. “The results of this prospective clinical trial approved under a Food and Drug Administration Investigational Device Exemption (IDE) confirmed the safety and efficacy outcomes previously reported in three European clinical trials and several independent publications both in isolated and combined procedure and in any surgical approach,” said Rakesh Suri, M.D., D.Phil., Cleveland Clinic and Cleveland Clinic Abu Dhabi. “From this prospective trial, the demonstrated hemodynamics and enhancements in patient quality of life support the practice and use of sutureless valves in patients with severe aortic valve stenosis.” “The study’s validating data provides further evidence that the use of the Perceval valve can lead to a significant reduction in cross-clamp time compared to the STS average,” said David Heimansohn, M.D., St. Vincent Heart Center, Indiana. “Since I began using the valve over three years ago, I have found that the use of Perceval is associated with a shorter procedure and recovery time, which allows patients to return back to their day-to-day lives more quickly.” The second presentation, “Sutureless Aortic Valves Versus Transcatheter Aortic Valve in Patients with Severe Aortic Stenosis and Intermediate Risk Profile: A Propensity Match Comparison in the Real World,” analyzed and compared the outcome of intermediate-risk aortic stenosis patients undergoing isolated sutureless and transcatheter aortic valve replacement (TAVR) implants. The study found that at 30-day follow up, patients treated with the sutureless valve had a significantly lower mortality rate. At mean follow up of 36 months, the overall survival and freedom from adverse events were significantly better among patients who underwent sutureless valve procedures. When compared to TAVR, the use of Perceval significantly improved patient outcomes for intermediate-risk patients with isolated aortic stenosis. “With Perceval’s technology, cardiac surgeons have a viable solution to standard bioprostheses that can decrease procedure time and reduce post-operative complications. These encouraging results demonstrated that the Perceval valve, when compared to TAVR, significantly improved patient outcomes for intermediate-risk patients with isolated aortic stenosis,” said Prof. Claudio Muneretto, M.D., University of Brescia Medical School, Italy. Adding to the growing Perceval evidence base, the data presentation, “Sutureless Aortic Valve Replacement in High Risk Patients Neutralizes Expected Worse Hospital Outcome: a Clinical Economic Analysis,” highlighted the clinical and economic impact of using the Perceval valve in high-risk patients compared to those who underwent sutured valve AVR with lower preoperative risk. The analysis found that, despite the higher patient risk profile in the Perceval group, the use of the sutureless valve resulted in no change to hospital mortality and hospital resources consumption compared to sutured valves. Finally, in addition to the Perceval sutureless valve data unveiled at AATS Week, Dr. Antonio Lio from Istituto Clinico S. Ambrogio, Milan, Italy presented a poster on a multicenter study from European and Asian centers demonstrating the benefits of the Memo 3D ReChord annuloplasty ring. As a prosthetic ring featuring an innovative chordal guiding system, the Memo 3D ReChord is used to treat patients with degenerative mitral valve disease. The study, “Early Outcomes of Mitral Valve Repair Using a New Prosthetic Ring with a Chordal Guiding System: A Multicenter Study,” showed that the use of Memo 3D ReChord during mitral valve repair procedures allowed surgeons to implant more accurately. With a short learning curve, use of the device could potentially improve surgical safety and shorten operation times for patients. To learn more about LivaNova and its portfolio of innovative cardiac solutions, please visit www.livanova.com. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. For more information, please visit www.livanova.com.


News Article | May 2, 2017
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has acquired the remaining outstanding interests in Caisson Interventional, LLC (“Caisson”), in support of LivaNova’s strategic growth initiatives. Based in Maple Grove, Minn., Caisson is a privately held clinical-stage medical device company focused on the design, development and clinical evaluation of a novel transcatheter mitral valve replacement (TMVR) implant with a fully transvenous delivery system. “We recognized the potential of the talented Caisson team and its technology several years ago. This team will now be the cornerstone for our planned entry into the TMVR space, which has the potential to be an important growth platform for us in the future,” said LivaNova’s CEO Damien McDonald. “We intend to invest in the clinical studies, regulatory approvals, product enhancements and other steps needed to launch this mitral valve replacement system commercially. We expect it will become a strategic complement to our heart valve portfolio for heart team physicians, allowing us to offer patients the most advanced, minimally invasive mitral valve replacement option.” Caisson’s device is unique, being the only TMVR product designed solely for trans-septal approach and delivered through a single venous access. The system is also designed for the implant to be fully retrieved following functional evaluation, but prior to final release – a safety feature important to physicians. “We created this percutaneous mitral valve replacement implant, procedure and delivery system to offer a significant new therapy to patients with severe mitral regurgitation,” said Caisson COO and Co-founder Todd Mortier. Caisson initiated its clinical trials through the U.S. FDA Early Feasibility Study program, and will add clinical sites in Europe and Canada. “We look forward to joining LivaNova to combine our efforts in bringing a superior technology to market,” added Caisson CEO and Co-founder C.J. Schweich, Jr., M.D. LivaNova has been an investor in Caisson since 2012 and has agreed to pay up to $72 million, net of $6 million of debt forgiveness, to acquire the remaining 51 percent of the company. The first payment of $18 million was made at closing with the balance paid on a schedule driven primarily by regulatory approvals and sales earn outs. As a result of the acquisition, LivaNova expects to recognize a pre-tax non-cash gain during the second quarter on the $15 million book value of its existing investment in Caisson. The acquisition will be dilutive to earnings for several years, but LivaNova fully anticipates this transaction will meet all long-term financial metrics and internal standards. 2017 guidance will be updated to include the estimated impact of the acquisition during LivaNova’s first quarter earnings call tomorrow morning. The Caisson TMVR system is not approved for sale in any country. LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively. This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company’s future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain. As a result, the Company’s actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning entry into the TMVR space, developing Caisson as an important growth platform, investing in the clinical studies, regulatory approvals, product enhancements and other steps needed to launch this mitral valve replacement system commercially, developing Caisson as a strategic addition to the Company’s heart valve portfolio, offering patients the most advanced, minimally invasive mitral valve replacement option, offering a significant new therapy to patients with severe mitral regurgitation, adding clinical study sites for Caisson’s TMVR device in Europe and Canada, bringing a superior technology to market, recognizing a pre-tax non-cash gain during the second quarter on the $15 million book value of its existing investment in Caisson, and anticipating that this transaction will meet all long-term financial metrics and internal standards. Important factors that may cause actual results to differ include, but are not limited to: (i) risks that the legacy businesses of Cyberonics, Inc. and Sorin S.p.A. (together, the “combined companies”) will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; (ii) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; (iii) risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; (iv) organizational and governance structure; (v) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (vi) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (vii) the ability to hire and retain key personnel; (viii) the ability to attract new customers and retain existing customers in the manner anticipated; (ix) the reliance on and integration of information technology systems; (x) changes in legislation or governmental regulations affecting LivaNova; (xi) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (xii) conditions in the credit markets; (xiii) business and other financial risks inherent to the industries in which LivaNova operates; (xiv) risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; (xv) LivaNova’s international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xvi) and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-4 and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results. All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. For more information, please visit www.LivaNova.com.


News Article | April 26, 2017
Site: www.eurekalert.org

Dr. Abbas Ardehali, a professor of surgery and medicine in the division of cardiothoracic surgery at the David Geffen School of Medicine at UCLA, has been selected a 2017 recipient of the Ellis Island Medal of Honor by the National Ethnic Coalition of Organizations. Ardehali will receive the award at ceremony on May 13 at historic Ellis Island in New York City. The medals are awarded annually to a group of distinguished U.S. citizens who exemplify a life dedicated to community service. These are individuals who preserve and celebrate the history, traditions and values of their ancestry while exemplifying the values of the American way of life, and who are dedicated to creating a better world. Since it was established in 1986, the Ellis Island Medal has been officially recognized by both Houses of Congress as one of the nation's most prestigious awards. Past recipients have included six U.S. presidents, former Secretary of State Hillary Clinton, as well as such notables as Frank Sinatra, Lee Iacocca, Quincy Jones, Muhammad Ali, Nobel laureate Elie Wiesel, Louis Zamperini and Rosa Parks. "I was surprised and honored to be informed that I was selected as a 2017 Ellis Island Medal of Honor awardee," said Ardehali. "I really think this recognition is a reflection of the accomplishments that our UCLA heart and lung transplant teams have achieved together." Ardehali serves as director of the UCLA Heart and Lung Transplant program, which was ranked as the largest combined heart and lung transplant program in the United States in 2016 by the United Network of Organ Sharing. Ardehali and his colleagues have been leaders in implementing new technologies to advance the field of heart and lung transplantation and have the depth of experience to take many of the more complex cases that other transplant centers are unable to accept. His professional accomplishments include a role in developing an innovative technology for transporting human heart and lungs in a beating or breathing state. The technology could help to improve clinical outcomes and expand the donor pool of organs to help patients. He also developed and patented a new technology that will improve the care of patients with end-stage lung disease. Ardehali has served as a volunteer on several committees for the United Network for Organ Sharing and several scientific organizations, with leadership positions in the International Society of Heart and Lung Transplantation, American Society of Transplant Surgeons, American Association of Thoracic Surgery and Society of Thoracic Surgeons. Among his many honors and awards, Ardehali received a Resolution of Commendation by the California State Assembly and the the Breath of Life Award from the Cystic Fibrosis Foundation. Ardehali has been a faculty member at UCLA since 1997. He also served as chief of cardiothoracic surgery at West Los Angeles Veterans Hospital from 1998 to 2012. He co-authored a textbook, "Khonsari's Cardiac Surgery: Safeguards and Pitfalls in Operative Technique," published in 2016. He has authored numerous book chapters and more than 100 peer-reviewed manuscripts and abstracts. Ardehali has been interviewed by ABC News, the Associated Press, CNN, Fox News, NBC News, CBS News, "The Doctor's Show," and Al Jazeera America. He completed his fellowship in cardiothoracic surgery at UCLA and his internal medicine residency at UC San Francisco. He earned a master's degree in public health at UC Berkeley; a medical degree at Emory University School of Medicine; and both a master's degree in chemical and biochemical engineering and an undergraduate degree in biology and biochemistry, both from Rutgers University. Born in Tehran, Iran, Ardehali moved to the United States when he was in high school. He and his wife, Mitra, who is a practicing dentist, have two daughters, Leila and Sara, currently attending Barnard College and Columbia University.


(PRLEAP.COM)– According to a new series of reports on the Japan patient monitoring device market by iData Research ( www.idataresearch.com ), reimbursement cuts and consolidation within the industry has reduced the total market opportunity, resulting in low market growth and declining average selling prices (ASP). Despite growing demand for quality patient monitoring solutions, some hospitals in Japan cannot afford high-cost monitoring platforms due to budget constraints."A prevailing trend across the region relates to the adoption of less-invasive, more accessible, patient-centric monitoring device configurations," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "Emphasis is now being placed on patient comfort and mobility across lower-acuity care settings, wherein gaps in monitoring are further being filled with portable solutions."Increased competitiveness within the total patient monitoring market has also had a negative impact on market growth. The entry of low cost foreign competition in Japan has been especially disruptive because tenders are frequently won on the basis of cost over quality. However, the long-term prospects remain positive as demand for increased levels of monitoring will enable unit sales growth to outpace pricing pressure. This positive outlook combined with fast growing segments such as telehealth and wireless ambulatory telemetry monitoring will facilitate accelerated market growth in the region over the next several years.Nihon Kohden is the leading competitor in the patient monitoring device and equipment market in Japan. They are the market leader in the multi-parameter vital sign monitoring market, the wireless ambulatory telemetry monitor market, the electromyography (EMG) market, the electroencephalogram (EEG) market and the fetal and neonatal monitoring market. Their extensive product line includes the CNS-9701™ and I™ for central monitoring, the I™ product line of bedside monitors, I™, AirEEG WEE-1000™, and Neurofax™ EEG product lines. Their strength in Japan can be attributed to their strong local sales force and good relationships with hospitals.Fukuda Denshi is the second leading competitor in the Japanese patient monitoring market. Having been involved in the medical instrument market for over 75 years, this Japanese company has acquired substantial market share in the vital signs monitoring, wireless ambulatory telemetry monitoring, and pulse oximetry monitoring markets. Fukuda Denshi offers monitors in the high-, mid- and low-acuity segments with their Dynascope™ product line. Their strength can be attributed to their strong presence in Japan, where their relationship with local customers and their reputation as a market leader in the electrocardiograph (ECG) market contributed to their strong position. Additional competitors in the Japan patient monitoring market include Philips Healthcare, Medtronic, Omron Healthcare, Natus Medical, Masimo and GE Healthcare among others.More on the patient monitoring device market in Japan can be found in a series of reports published by iData Research entitled the Japan Market Report Suite for Patient Monitoring Equipment . The suite covers reports on the following markets: multi-parameter vital signs monitoring, wireless ambulatory telemetry monitoring, electromyogram monitoring, electroencephalogram monitoring, fetal and neonatal monitoring, pulse oximetry.The iData report series on patient monitoring devices covers the U.S., China, Australia, India, Japan, South Korea and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about patient monitoring device market data, register online or email us at info@idataresearch.net for a Japan Market Report Suite for Patient Monitoring Equipment brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Ophthalmics, Vascular Access, Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


(PRLEAP.COM)– According to a new series of reports on the Japan market for gynecological devices by iData Research ( www.idataresearch.com ), the investment in cutting-edge technology fueled by exponential patient demand has led to increasing patient growth in the assisted reproduction technology (ART) device segment. However, despite Japan's preference to invest in high-end medical devices, the gynecology device market is constrained by the lack of training, diversity in alternative procedures and investment in specialty equipment.The ART market specifically is being heavily impacted by numerous mergers and acquisitions, creating monopolies on prices and market shares in the region. Ultimately, the predominant shift towards capital equipment that can be used off-label across procedure types is limiting the overall ART capital equipment sales in Japan."The number of assisted reproduction procedures conducted in Japan is projected to increase fueled by decreasing fertility rates, a higher average age of women who want to become pregnant, government funding and new technology," explains Dr. Kamran Zamanian, CEO of iData. "However, the average selling price (ASP) of ART devices per unit is declining due to price erosion."Changes to reimbursement rates as well as regulations in Japan are highly anticipated, but unlikely to occur in the immediate future. While the government and the Japan Society of Obstetrics and Gynecology (JSOG) are both promoting assisted reproduction technology in an effort to promote an increasing national birth rate, traditional cultural values hinder the acceptance of an expanded definition for families. Single individuals and same-sex couples are ineligible to receive in-vitro fertilization (IVF) treatment in Japan. While cultural attitudes are slowly changing, it is unlikely the regulations will be updated anytime soon. This is further fueling the reproduction tourism market outside of Japan.Kitazato is the largest competitor in the Japanese assisted reproduction device market with a wide portfolio of products specializing in ART, the oocyte retrieval needles include pump aspiration single lumen, manual aspiration single lumen, double lumen, and other needles. Kitazato is the established competitor within the Japanese market, holding a monopoly on certain distribution networks and clinics. Their market share is projected to decline throughout the reporting period as foreign competitors continue to gain market share.Cook Medical is the second leading competitor in the Japanese assisted reproduction market. This company has over 15 different retrieval needles available in various product lines, including their Disposable EchoTip® Lancet Needle, standard EchoTip® needles and the Ova-Stiff™ Ovum Aspiration needles. Additional competitors in the Japan assisted reproduction market include Cooper Surgical, Vitrolife and Irvine Scientific among others.More on the gynecological devices market in Japan can be found in a series of reports published by iData Research entitled the Japan Market Report Suite on Gynecological Devices . The suite covers reports on the following markets: assisted reproduction technology, endometrial resection, uterine fibroid embolization, hysteroscopes, colposcopes, female urinary incontinence slings, pelvic organ prolapse.The iData report series on gynecological devices covers the U.S., China, Australia, Brazil, Japan, South Korea, India, Latin America and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about gynecological devices market data or procedure data, register online or email us at info@idataresearch.net for a Japan Market Report Suite on Gynecological Devices brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.


(PRLEAP.COM)– According to a new series of reports on the Brazil dental bone graft substitutes and barrier membrane market by iData Research ( www.idataresearch.com ), the market is largely limited by the cost of procedures. While the vast majority of companies that distribute dental membranes strongly recommend the use of membranes in every bone grafting procedure, dentists are often hesitant to add cost and avoid the use of membranes if it is not clinically necessary."While membranes increase the likelihood that the procedure will be successful, they represent an additional expense that patients and insurers are not always willing to accept," explains Jeffrey Wong, Strategic Analyst Manager at iData Research. "However, the increasing preference of resorbable materials over their non-resorbable counterparts is encouraging growth in this market as bio-absorbable membranes are offered at a price premium."An ongoing trend to deal with the high cost of dental bone graft procedures within Brazil is the continued presence of off-label sales. Offered by what has been described as "copy-cat brands", these bone grafts are labeled as generic or bioequivalent to premium brands. A common example would be an imitation of the Bio-Oss® product originally offered by Geistlich. Imitation products will continue to be a significant cornerstone of the dental market in Brazil as price sensitivity remains a major concern, greatly depressing the overall average selling price (ASP) of bone graft substitutes.As many customers tend to rely on off-label products, the market potential is further limited by the competitive edge of these brands. New entrants into the market must face off-label sales as their major competition, which may be difficult to overcome. To counteract these imitation products and assure tissue quality, Brazil regulation agencies have tightened their guidelines. However, these guidelines tend to be intimidating as doctors are required to report and process copious amounts of information, which they would rather avoid. Bans on imported allograft products, and removal of allografts previously offered by local companies, ensure that there is no way around the hassle associated with utilizing this category of bone grafts.The dental bone graft substitute and barrier membrane markets in Brazil are largely controlled by tissue banks and 4 main companies: Geistlich, Critéria, Baumer and Zimmer Biomet. In addition to their current dominance in the market, they are also very active with ongoing acquisitions to further secure their leading positions. Geistlich is the market leader in both the dental bone graft substitute and dental membrane markets in Brazil. Geistlich benefited from selling the most recognized brand of dental bone graft material, Bio-Oss®, which allowed it to hold significant market share in the xenograft segment. Aside from manufacturing consolidation, emerging competitors continue to gain market share through competitive pricing. Success in the Brazilian market will depend on who can capture market share based on not only price but also functionality. Examples of this include gradually emerging submarkets such as xenografts, growth factors and resorbable dental membranes. Additional competitors in the Brazil dental bone graft substitute market include Straumann, Nobel Biocare and Sistema INP among others.More on the dental bone graft substitutes market in Brazil can be found in a series of reports published by iData Research entitled the Brazil Market Report Suite for Dental Bone Graft Substitutes and Other Biomaterials . The suite covers reports on the following markets: dental bone graft substitutes and dental barrier membranes as well as an appendix on the dental growth factor market.The iData report series on dental bone graft substitutes covers the U.S., China, Australia, Japan, South Korea, Brazil, Mexico, Argentina and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players' success strategies in each market and segment. To find out more about dental bone graft substitute market data, register online or email us at info@idataresearch.net for a Brazil Market Report Suite for Dental Bone Graft Substitutes and Other Biomaterials brochure and synopsis.iData Research ( www.idataresearch.com ) is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Endoscopy, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more.We have built a reputation and earned our clients' trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.

Loading Cardiac Surgery collaborators
Loading Cardiac Surgery collaborators